Report
MaaT Pharma Constipated clinical tract in the US
The FDA maintains its clinical hold on the US arm of MaaT013's Phase III trial, holding on to concerns with regards to the company's sample “pooling” process, likely driven by fears for unidentified pathogen risk in the material. Although we continue to see long-term potential in MaaT's technology, we lower our US probability of success given the FDA's stance and adjust our PT to €11 while adopting an Accumulate rating.
Underlying
MAAT PHARMA SA
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Thomas Vranken
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.